Bill
Bill > A2337
NJ A2337
NJ A2337Requires health insurers to limit patient cost-sharing and provide appeal process concerning certain prescription drug coverage.
summary
Introduced
02/04/2016
02/04/2016
In Committee
10/06/2016
10/06/2016
Crossed Over
Passed
Dead
01/08/2018
01/08/2018
Introduced Session
2016-2017 Regular Session
Bill Summary
This bill requires certain health insurers, under certain policies or contracts that provide coverage for prescription drugs, to place limitations on covered persons' cost sharing for prescription drugs. The bill's provisions apply to the following insurers and programs that provide coverage for prescription drugs under a policy or contract: health, hospital and medical service corporations; commercial individual and group health insurers; health maintenance organizations; health benefits plans issued pursuant to the New Jersey Individual Health Coverage and Small Employer Health Benefits Programs; the State Health Benefits Program (SHBP) and the School Employees' Health Benefits Program (SEHBP). Unless the plan or contract is required to provide bronze level of coverage or is a catastrophic plan under the federal Affordable Care Act, the bill requires insurers to ensure that plans limit a covered person's out-of-pocket financial responsibility, including any copayment or coinsurance, for prescription drugs, including specialty drugs, to no more than $100 per month for each prescription drug for up to a 30-day supply of any single drug. If the plan or contract is required to provide a bronze level of coverage, as defined in 45 C.F.R. s.156.140, the plan shall ensure that any required enrollee cost-sharing, including any copayment or coinsurance, does not exceed $200 per month for each prescription drug for up to a 30-day supply of any single drug. In the case of a plan that meets the requirements of a catastrophic plan, as defined in 45 C.F.R. s.156.155, it is exempt from these requirements. In the case of high-deductible plans, these cost sharing limits apply at any point in the benefit design, including before and after any applicable deductible is reached. For prescription drug benefits offered in conjunction with a high-deductible health plan, the plan shall not provide prescription drug benefits until the expenditures applicable to the deductible under the plan have met the amount of the minimum annual deductibles in effect for self-only and family coverage under section 223(c)(2)(A)(i) of the federal Internal Revenue Code (26 U.S.C. 223(c)(2)(A)(i)) for self-only and family coverage, respectively. Once the foregoing expenditure amount has been met under the plan, coverage for prescription drug benefits shall begin, and the limit on out-of-pocket expenditures for prescription drug benefits would be as specified in the bill. The bill also requires the plans to implement an exceptions process that allows enrollees to request an exception to any formulary, which exception shall permit a nonformulary drug to be deemed covered under the formulary if the prescribing physician determines that the formulary drug for treatment of the same condition either would not be as effective for the enrollee or would have adverse effects for the enrollee, or both. If an enrollee is denied such an exception, that denial is deemed an adverse determination that will be subject to appeal.
AI Summary
This bill requires certain health insurers, under certain policies or contracts that provide coverage for prescription drugs, to place limitations on covered persons' cost sharing for prescription drugs. The key provisions are:
1. Limits out-of-pocket costs for prescription drugs, including specialty drugs, to no more than $100 per month for up to a 30-day supply, with exceptions for bronze-level and catastrophic plans.
2. Applies these cost-sharing limits at any point in the benefit design, including before and after any applicable deductible is reached, except for high-deductible health plans.
3. Requires an exceptions process to allow enrollees to request coverage of a non-formulary drug if the prescribing physician determines the formulary drug would not be as effective or would have adverse effects.
4. Applies these requirements to various types of health insurance plans, including hospital, medical, individual, group, and small employer plans, as well as the State Health Benefits Program and School Employees' Health Benefits Program.
The bill aims to make prescription drugs more affordable for consumers by limiting their out-of-pocket costs, while also providing an exceptions process to ensure access to non-formulary drugs when medically necessary.
Committee Categories
Business and Industry
Sponsors (21)
Daniel Benson (D)*,
Jon Bramnick (R)*,
BettyLou DeCroce (R)*,
Timothy Eustace (D)*,
Reed Gusciora (D)*,
Angelica Jimenez (D)*,
Raj Mukherji (D)*,
Valerie Vainieri Huttle (D)*,
Ralph Caputo (D),
JoAnn Downey (D),
Eric Houghtaling (D),
Mila Jasey (D),
Gordon Johnson (D),
Sean Kean (R),
John McKeon (D),
Angela Mcknight (D),
Nancy Muñoz (R),
Elizabeth Muoio (D),
Holly Schepisi (R),
L. Grace Spencer (D),
Andrew Zwicker (D),
Last Action
Assembly Financial Institutions and Insurance Hearing (10:00 10/6/2016 Committee Room 16, Fourth Floor) (on 10/06/2016)
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| BillText | https://www.njleg.state.nj.us/2016/Bills/A2500/2337_I1.HTM |
| Bill | https://www.njleg.state.nj.us/2016/Bills/A2500/2337_I1.PDF |
Loading...